Gilead Sciences, Inc. $GILD Stock: Danske Bank A S Grows Stake

Danske Bank A S increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 27.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,068,347 shares of the biopharmaceutical company's stock after acquiring an additional 227,947 shares during the quarter. Danske Bank A S owned about 0.09% of Gilead Sciences worth $159,237,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in GILD. Bank of Nova Scotia acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at $100,056,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Gilead Sciences during the second quarter worth $55,754,000. Groupe la Francaise grew its stake in shares of Gilead Sciences by 30.9% during the second quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company's stock worth $6,270,000 after purchasing an additional 11,712 shares during the period. Baird Financial Group Inc. grew its stake in shares of Gilead Sciences by 3.6% during the second quarter. Baird Financial Group Inc. now owns 292,295 shares of the biopharmaceutical company's stock worth $36,929,000 after purchasing an additional 10,206 shares during the period. Finally, Headlands Technologies LLC bought a new stake in Gilead Sciences in the second quarter valued at about $6,251,000. Institutional investors own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. UBS Group increased their target price on Gilead Sciences from $175.00 to $195.00 and gave the company a "buy" rating in a research note on Friday, October 30th. HSBC boosted their target price on Gilead Sciences from $155.00 to $175.00 and gave the stock a "buy" rating in a research report on Thursday, September 10th. BMO Capital Markets reaffirmed an "outperform" rating and issued a $184.00 price target on shares of Gilead Sciences in a research note on Friday, October 30th. Needham & Company LLC set a $175.00 price target on Gilead Sciences in a research note on Friday, October 30th. Finally, Truist Financial increased their price target on shares of Gilead Sciences from $158.00 to $181.00 and gave the company a "buy" rating in a research report on Friday, October 30th. Twenty-three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $171.07.

More Gilead Sciences News

Investors following GILD have been watching these news items:

• Positive Sentiment: Zacks Research raised several forecasts, including FY2027 EPS to $9.42 from $9.36 and FY2028 EPS to $9.69 from $9.66. It also made small upward adjustments to quarterly estimates. The revisions suggest slightly improved expectations, though the analyst’s Hold rating tempers the signal.
• Neutral Sentiment: Gilead announced a partnership with TelevisaUnivision to promote HIV-prevention awareness at the Latin GRAMMY Awards. It may build awareness, but the announcement does not specify a direct near-term financial impact. Read More..
• Neutral Sentiment: A broader pharmaceutical-stock article highlighted Gilead’s dividend and pipeline as defensive attributes, but offered no company-specific new financial or operating catalyst. Read More..

Gilead Sciences Trading Up 0.1%

Shares of GILD traded up $0.13 during trading hours on Friday, reaching $168.08. The stock had a trading volume of 3,637,311 shares, compared to its average volume of 6,772,945. The company has a quick ratio of 1.22, a current ratio of 1.38 and a debt-to-equity ratio of 1.84. Gilead Sciences, Inc. has a 52 week low of $116.88 and a 52 week high of $176.58. The firm has a 50-day moving average of $155.10 and a 200 day moving average of $141.80. The company has a market cap of $208.48 billion, a P/E ratio of -53.19 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The business had revenue of $8.30 billion for the quarter, compared to the consensus estimate of $7.81 billion. During the same quarter last year, the business posted $2.47 EPS. The firm's revenue was up 6.8% compared to the same quarter last year. On average, sell-side analysts expect that Gilead Sciences, Inc. will post -0.98 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.0%. Gilead Sciences's dividend payout ratio (DPR) is currently -103.80%.

Insider Buying and Selling at Gilead Sciences

In related news, EVP Wettan Keeley M. Cain sold 3,399 shares of the company's stock in a transaction on Friday, November 6th. The shares were sold at an average price of $164.11, for a total value of $557,809.89. Following the completion of the transaction, the executive vice president directly owned 5,360 shares of the company's stock, valued at approximately $879,629.60. This represents a 38.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O'Day sold 102,619 shares of the stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $175.16, for a total value of $17,974,744.04. Following the transaction, the chief executive officer owned 551,683 shares of the company's stock, valued at approximately $96,632,794.28. This trade represents a 15.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 242,709 shares of company stock worth $39,503,427 over the last three months. Company insiders own 0.30% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.